Nov 9, 2021, 15:44 PM by

Qlucore AB (public) (“Qlucore” or “Company”) has today received approval of the application for listing of Qlucore shares on the Nasdaq First North Growth Market. The first day of trading of the shares will be 5th November 2021. Trading will be done with the ticker QCORE.

Nov 9, 2021, 15:44 PM by

Pillar VC and Petri have announced the winners of the $200K Pitch Competition that took place during the Founder-Led Biotech Summit, a free virtual event that brought together biotech founders, faculty, PhDs, scientists, investors, and executives to support the founder-led biotech movement.

Nov 9, 2021, 15:44 PM by

Nov 9, 2021, 15:44 PM by

The Community Blood Center is the latest regional blood center to embrace biolog-id’s technology. Biolog-id’s solution for platelet lifecycle management will be deployed to support the efficiency of platelet manufacturing, documentation, and inventory management.

Nov 9, 2021, 15:44 PM by

Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against COVID-19.

Nov 5, 2021, 01:00 AM by User Not Found

Bio-IT World | Using genetic sequencing to identify pathogens and respond to outbreaks is hardly new. The emergence of the SARS-CoV-2 in late 2019 was a game-changer, however. While SARS-CoV-2 was identified and sequenced in record time, it proved impossible to contain. It quickly became apparent that existing surveillance systems were not up to the task of tracking a fast-moving virus that spread asymptomatically. The speed and scale of Coronavirus spread provided a wake-up call highlighting our vulnerability to a global pandemic. But bioinformatics plays a crucial role.

Nov 3, 2021, 01:00 AM by User Not Found

Bio-IT World | Researchers at the University of Buffalo (UB) have come up with a nanoparticle platform for oral prophylactic immunotherapy designed to pre-expose the immune system to medications it might otherwise perceive as foreign and attack. If translated to the clinic, their novel “reverse vaccination” approach could be used to desensitize patients to key proteins in drug treatments for rare conditions, autoimmune diseases, and allergies.

Nov 2, 2021, 01:00 AM by User Not Found

Bio-IT World | CRISPR partnership with Vertex Pharmaceuticals, new public biotech fund, life sciences analytics cloud, immune target validation, single cell analysis, and more.

Oct 29, 2021, 01:00 AM by User Not Found

Bio-IT World | Pistoia sets new life sciences strategy, Charles River Labs announces cryo-EM partnership, and Vertex and Mammoth launch CRISPR partnership. Plus new products from Waters, PerkinElmer, Thermo Scientific and more.

Oct 28, 2021, 01:00 AM by User Not Found

Bio-IT World | A “quiet revolution” has been underway over the past year, exponentially growing the number of genetic variants discoverable by genome sequencing, according to Stephen Kingsmore, M.D., president and CEO of Rady Children's Institute for Genomic Medicine in San Diego. Notably, it is now possible to identify an enormous number of structural variants—large genomic alterations that include insertions, deletions, and copy number variations—which account for about 20% of diagnoses in the neonatal intensive care unit (NICU).

Oct 26, 2021, 01:00 AM by User Not Found

Bio-IT World | Krista McKee’s 20-year career in pharma has steadily taken her on a trajectory toward data science. She is currently Head of Insights and Analytics at Takeda’s Data Sciences Institute (DSI). She recently sat down to discuss how Takeda is recognizing the importance of data alignment and accessibility and the choreography necessary to keep it all moving forward.

Oct 22, 2021, 01:00 AM by User Not Found

Bio-IT World | Increasingly, the discovery and development of new medicines is embracing bioactive modalities beyond traditional small molecules, both as therapeutic agents and delivery mechanisms. I propose that the industry create standards that describe not only how experimental and substance data should be treated but also cover the services that provide access to that data.

Oct 21, 2021, 15:53 PM by User Not Found

Bio-IT World | Funded by an anonymous $50 million gift, the University of California, Berkeley and UC San Francisco yesterday announced a joint program in computational precision health.

Oct 20, 2021, 01:00 AM by User Not Found

Bio-IT World | At the Bio-IT World Conference & Expo last month, Aleksandar Stojmirovic and Weiwei Schultz, both of Janssen’s Data Science group, explained the data management mission and vision of Janssen R&D.

Oct 19, 2021, 01:00 AM by User Not Found

Bio-IT World | University at Buffalo (UB) researchers plan to commercialize a platform for site-of-injury pain relief that targets nerve endings, the starting point of pain signaling, using lipidated peptides (peptides modified with lipid molecules) that prevent overexcitement of pain neurons.

Oct 15, 2021, 16:51 PM by

Oct 15, 2021, 16:51 PM by

Oct 15, 2021, 16:51 PM by

CluePoints, the premier provider of risk-based quality management (RBQM) and data oversight software for clinical trials, has partnered with ZS, a global professional services firm with technology and analytics expertise in biopharma, to offer innovative capabilities in portfolio-level performance oversight.  The new partnership pairs a best-in-breed solutions company focused on study-level risk-based management with a pharmaceutical and biotech solutions provider with advanced capabilities in portfolio-level quality and operational oversight.

Oct 15, 2021, 16:51 PM by

Oct 15, 2021, 16:51 PM by

Certara’s Simcyp COVID-19 Vaccine Model uses biosimulation to improve decision-making and help optimize dosing regimens of COVID-19 vaccines. Certara calibrated its model using the structure of actual COVID-19 vaccines and validated it by replicating the published clinical data. The model, which is incorporated in Certara’s Vaccine Simulator™, addresses important questions such as differences in response with age and ethnicity, optimal timing between doses and expected duration of antibody response.